Cargando…

c-Fos and Dusp1 confer non-oncogene addiction in BCR-ABL induced leukemia

Tyrosine kinase inhibitor (TKI) therapy for human cancers is not curative, with relapse due to the continuing presence of tumor cells, referred to as minimal residual disease (MRD) cells. MRD stem or progenitor cells survival in the absence of oncogenic kinase signaling, a phenomenon referred to as...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kesarwani, Meenu, Kincaid, Zachary, Gomaa, Ahmed, Huber, Erika, Rohrabaugh, Sara, Siddiqui, Zain, Bouso, Muhammad F., Latif, Tahir, Xu, Ming, Komurov, Kakajan, Mulloy, James C., Cancelas, Jose A., Grimes, H. Leighton, Azam, Mohammad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5424814/ https://www.ncbi.nlm.nih.gov/pubmed/28319094 http://dx.doi.org/10.1038/nm.4310

Ejemplares similares

Enhanced MAPK signaling is essential for CSF3R induced leukemia
por: Rohrabaugh, Sara, et al.
Publicado: (2016)

KLF5 controls glutathione metabolism to suppress p190-BCR-ABL+ B-cell lymphoblastic leukemia
por: Zhang, Cuiping, et al.
Publicado: (2018)

MEK/ERK addiction in CNL/aCML
por: Kesarwani, Meenu, et al.
Publicado: (2017)

S6K1 determines the metabolic requirements for BCR-ABL survival
por: Barger, Jennifer F., et al.
Publicado: (2012)

An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system
por: Choi, Kwangmin, et al.
Publicado: (2017)

Combined inhibition of BCR-ABL1 and the proteasome as a potential novel therapeutic approach in BCR-ABL positive acute lymphoblastic leukemia
por: Maletzke, Saskia, et al.
Publicado: (2022)

Rational polypharmacological targeting of FLT3, JAK2, ABL, and ERK1 suppresses the adaptive resistance to FLT3 inhibitors in AML
por: Azhar, Mohammad, et al.
Publicado: (2022)

Momelotinib is a highly potent inhibitor of FLT3-mutant AML
por: Azhar, Mohammad, et al.
Publicado: (2022)

Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I
por: Mian, Afsar Ali, et al.
Publicado: (2012)

Targeting BCR-ABL(+) stem/progenitor cells and BCR-ABL-T315I mutant cells by effective inhibition of the BCR-ABL-Tyr177-GRB2 complex
por: Chen, Min, et al.
Publicado: (2017)

Revealing static and dynamic modular architecture of the eukaryotic protein interaction network
por: Komurov, Kakajan, et al.
Publicado: (2007)

Patterns of human gene expression variance show strong associations with signaling network hierarchy
por: Komurov, Kakajan, et al.
Publicado: (2010)

BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene
por: Sharma, Nitesh, et al.
Publicado: (2015)

Pterostilbene downregulates BCR/ABL and induces apoptosis of T315I-mutated BCR/ABL-positive leukemic cells
por: Kawakami, Shohei, et al.
Publicado: (2022)

BCR: a new target in resistance mediated by BCR/ABL-315I?
por: Haberbosch, Isabella, et al.
Publicado: (2016)

The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins
por: You, Liangshun, et al.
Publicado: (2016)

Expanding the Diversity of Allosteric Bcr-Abl Inhibitors
por: Deng, Xianming, et al.
Publicado: (2010)

An In-House Method for Molecular Monitoring of BCR-ABL
por: Sercan, Hakkı Ogün, et al.
Publicado: (2012)

Depression of oncogenecity by dephosphorylating and degrading BCR-ABL
por: Gao, Miao, et al.
Publicado: (2016)

AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells
por: Zhou, Liang L., et al.
Publicado: (2008)

The HSP90 inhibitor KW-2478 depletes the malignancy of BCR/ABL and overcomes the imatinib-resistance caused by BCR/ABL amplification
por: Zeng, Dachuan, et al.
Publicado: (2022)

Selective DNA methylation in cancers controls collateral damage induced by large structural variations
por: Mohanty, Vakul, et al.
Publicado: (2016)

Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1(T315I) and BCR-ABL1(T315I-E255K)
por: Mian, Afsar Ali, et al.
Publicado: (2021)

Effect of Ras Inhibition in Hematopoiesis and BCR/ABL Leukemogenesis
por: Baum, Karina J, et al.
Publicado: (2008)

Induction of apoptosis by directing oncogenic Bcr-Abl into the nucleus
por: Huang, Zheng-Lan, et al.
Publicado: (2013)

IGF-IR determines the fates of BCR/ABL leukemia
por: Xie, Jingjing, et al.
Publicado: (2015)

Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid Leukemia
por: Polillo, Marialuisa, et al.
Publicado: (2015)

Bcr-Abl tyrosine kinase inhibitors- current status
por: Mughal, Anum, et al.
Publicado: (2013)

Transcriptomic classes of BCR-ABL1 lymphoblastic leukemia
por: Kim, Jaeseung C., et al.
Publicado: (2023)

The Functional Interplay Between the t(9;22)-Associated Fusion Proteins BCR/ABL and ABL/BCR in Philadelphia Chromosome-Positive Acute Lymphatic Leukemia
por: Rafiei, Anahita, et al.
Publicado: (2015)

Targeting the PTP1B‐Bcr‐Abl1 interaction for the degradation of T315I mutant Bcr‐Abl1 in chronic myeloid leukemia
por: Elgehama, Ahmed, et al.
Publicado: (2022)

Use of Data-Biased Random Walks on Graphs for the Retrieval of Context-Specific Networks from Genomic Data
por: Komurov, Kakajan, et al.
Publicado: (2010)

Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr/Abl-dependent and Bcr/Abl-independent mechanisms
por: Lan, Xiaoying, et al.
Publicado: (2016)

A Small Molecule Inhibitor, OGP46, Is Effective against Imatinib-Resistant BCR-ABL Mutations via the BCR-ABL/JAK-STAT Pathway
por: Wei, Liuya, et al.
Publicado: (2020)

A Novel ELISA-Based Peptide Biosensor Assay for Screening ABL1 Activity in vitro: A Challenge for Precision Therapy in BCR-ABL1 and BCR-ABL1 Like Leukemias
por: Montecchini, Oksana, et al.
Publicado: (2021)

NetWalker: a contextual network analysis tool for functional genomics
por: Komurov, Kakajan, et al.
Publicado: (2012)

Fine-Scale Dissection of Functional Protein Network Organization by Statistical Network Analysis
por: Komurov, Kakajan, et al.
Publicado: (2009)

Recent advances in the bcr-abl negative chronic myeloproliferative diseases
por: Bennett, Michael, et al.
Publicado: (2006)

Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia
por: Hoelbl, Andrea, et al.
Publicado: (2010)

Deletion of ABL/BCR on der(9) associated with severe basophilia
por: Vaidya, Shantashri, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_vbluq30eee36otp2vnuiaij26e